Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
    Meeting Abstract

    Shoushtari, A. N.; Middleton, M. R.; Hamid, O.; Meier, F.; Bauer, T.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
    Meeting Abstract

    Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Meeting Abstract

    Orloff, M.; Watkins, C.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Gama, J.; Butler, M. O.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
    Meeting Abstract

    Huang, R.; Youssef, G.; Nelson, T.; Wen, P.; Forsyth, P.; Hodi, F. S.; Margolin, K. A.; Algazi, A. P.; Hamid, O.; Lao, C. D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Perspectives and strategies to minimize harm from melanoma diagnosis
    Editorial

    Busam, K. J.; Gerami, P.; Scolyer, R. A.
    JAMA Dermatology (2023)

    Fulltext@MSK | Save
  • T cell receptor therapeutics: Immunological targeting of the intracellular cancer proteome
    Review

    Klebanoff, C. A.; Chandran, S. S.; Baker, B. M.; Quezada, S. A.; Ribas, A.
    Nature Reviews Drug Discovery (2023)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial
    Journal Article

    Vos, J. L.; Burman, B.; Jain, S.; Fitzgerald, C. W. R.; Sherman, E. J.; Dunn, L. A.; Fetten, J. V.; Michel, L. S.; Kriplani, A.; Ng, K. K.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save